These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 4136394)

  • 21. [Clinical and experimental studies of the influence of Cl-inactivator on the euglobulin clot lysis time (author's transl)].
    Takeda S; Katoh H; Takaki A; Nouzuka Y; Ohsato K
    Rinsho Ketsueki; 1979 Aug; 20(8):879-85. PubMed ID: 502003
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of human serum plus streptokinase on spontaneous pulmonary metastases of Vx2 carcinomas transplanted in the maxillary sinus of the rabbit.
    Sugimura M; Tsubakimoto ; Kashibayashi Y; Kawakatsu K
    Int J Oral Surg; 1975 Jul; 4(3):112-20. PubMed ID: 808504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Action of the plasma of hyperthyroid patients on fibrinolysis activated with streptokinase (SK). Thromboelastographic findings].
    Cacciola E; Terranova R; Giustolisi R
    Boll Soc Ital Biol Sper; 1967 Jan; 43(2):74-6. PubMed ID: 6049567
    [No Abstract]   [Full Text] [Related]  

  • 24. [On euglobulin fibrinolysis. II. The characteristics of euglobulin fibrinolysis in arterisclerotic subjects].
    CAMERADA P; CONGIU M; LEO P
    Boll Soc Ital Biol Sper; 1959 Nov; 35():1373-5. PubMed ID: 13807117
    [No Abstract]   [Full Text] [Related]  

  • 25. The differentiation of esterase and fibrinolytic activity in human plasma euglobulin preparations.
    Harpel P
    Thromb Diath Haemorrh; 1968 Jul; 19(3):596-8. PubMed ID: 4236827
    [No Abstract]   [Full Text] [Related]  

  • 26. [On euglobulin fibrinolysis. I. The characteristics of euglobulin fibrinolysis in normal man].
    CAMERADA P; CONGIU M; LEO P
    Boll Soc Ital Biol Sper; 1959 Nov; 35():1370-3. PubMed ID: 13807116
    [No Abstract]   [Full Text] [Related]  

  • 27. [Activation and inhibition of buffy crust fibrinolysis in vitro].
    Harms D
    Gegenbaurs Morphol Jahrb; 1968; 111(3):488-92. PubMed ID: 4232858
    [No Abstract]   [Full Text] [Related]  

  • 28. Blood fibrinolytic system in rana tigrina.
    Srivastava VM; Dube B; Dube RK; Agarwal GP; Ahmad N
    Thromb Haemost; 1981 Jun; 45(3):252-4. PubMed ID: 7281104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

  • 31. Diurnal variation in plasma euglobulin activity and fibrinogen levels. Preliminary report.
    HAJJAR GC; WHISSEN NC; MOSER KM
    Angiology; 1961 May; 12():160-4. PubMed ID: 13710622
    [No Abstract]   [Full Text] [Related]  

  • 32. [Fibrinolysis by nicotinic acid derivatives].
    Thies HA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(2):216-9. PubMed ID: 4106011
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of blood serum antiplasmin and euglobulins on fibrinolysis and fibrinogenolysis in vitro].
    Bratus' GM; Gorodetskiĭ AL; Byshevskiĭ ASh
    Vopr Med Khim; 1971; 17(5):547-9. PubMed ID: 4256467
    [No Abstract]   [Full Text] [Related]  

  • 34. Amidolytic activity of plasma euglobulins.
    Jasielczuk J; Dabrowka M; Gacko M; Jankiewicz M
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():250-1. PubMed ID: 15638440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leukofibrinolysis.
    Lewis JH; Szeto IL; Bayer WL; Curiel DC
    Blood; 1972 Dec; 40(6):844-55. PubMed ID: 4263716
    [No Abstract]   [Full Text] [Related]  

  • 36. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
    Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LIPOPROTEINS AND FIBRINOLYSIS.
    HOWELL M
    Proc R Soc Med; 1964 Jul; 57(7):606-9. PubMed ID: 14178953
    [No Abstract]   [Full Text] [Related]  

  • 38. [Changes in the euglobulin fibrinolysis time during interruption of pregnancy after intravenous injection of EACA].
    Howorka E; Wyrzykiewicz T
    Wiad Lek; 1968 Jul; 21(13):1129-32. PubMed ID: 5670520
    [No Abstract]   [Full Text] [Related]  

  • 39. [The effect of heparin on fibrin clot stabilization].
    Rustamova BA; Molchanova LV; Kudriashov BA
    Vopr Med Khim; 1970; 16(3):290-3. PubMed ID: 4247924
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and activity of dipeptides containing epsilon-aminocaproic acid.
    Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1994; 51(6):499-504. PubMed ID: 7762400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.